Metabolic reprogramming is now recognized as a hallmark of cancer, playing a pivotal role in tumor progression, therapeutic resistance, immune evasion, and ...

A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms by which a major oncogene ...

A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms by which a major oncogene ...

A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms by which a major oncogene ...

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only ...

Led by University of Michigan researchers, a study in Cancer Cell identified a new target for Group-3 medulloblastomas. The results help identify new therapeutic avenues for treating these deadly ...

Medulloblastomas are one of the most common childhood brain cancers. Group-3 medulloblastomas are particularly aggressive and ...

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer, spotlighting its potential as a multidimensional ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Treatment with the CDK4/6 inhibitor palbociclib led to downregulation of MYC-regulated HR repair pathway genes as well as reduced RAD51 ... in those ovarian cancer cell lines that demonstrated ...